Inventiva's Financial Overview for Q3 2024

Inventiva has disclosed its financial status for the third quarter of 2024. As of September 30, cash and equivalents were at €13.9 million. Revenues for the first nine months reached €1.3 million, reflecting a decrease compared to last year. The firm issued royalty certificates worth €20.1 million in July. A significant equity raise brought in €94.1 million, ensuring operational funding until Q2 2025.

The clinical-stage biopharmaceutical company, known for its work on MASH/NASH treatments, spent €71.7 million on R&D, a 10% reduction from last year's figures due to paused patient recruitment and trial completions. Financing activities yielded €42.3 million mainly from European Investment Bank agreements.

Inventiva anticipates further financial extension from a planned equity raise in December, projecting operations could be sustained until mid-Q3 2025.